Johnson & Johnson vs Roivant Sciences Ltd.
JNJ vs ROIV — side-by-side comparison from reported financials. JNJ leads 6, ROIV leads 3 of 9 comparable metrics.
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
Roivant Sciences Ltd.
ROIV · Healthcare
$35.44+3.60%Strong
| Metric | JNJ | ROIV |
|---|---|---|
| Price | $261.79 | $35.44 |
| Market cap | $631B | $25.6B |
| Revenue (TTM) | $97.9B | $16.9M |
| Revenue growth | +5.6% | -48.7% |
| Net margin | 21.5% | -7594.2% |
| Free cash flow | $22.2B | -$1.89B |
| Net cash (debt) | ($27.8B) | $3.73B |
| 1-year price return | +37.0% | +119.9% |
| P/E | 29.9 | — |
| P/E vs own history (cheap-side %) | 16% | 73% |
| Dividend yield | 2.00% | — |
| Return on equity | 26% | -6% |
| Altman Z-score | — | 40.50 |
| CV checks passed | 10 of 11 | 5 of 11 |
| Employees | 140,800 | 721 |
Full résumé-style profiles: JNJ CV · ROIV CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.